BHC(600721)2024-04-25 10:42Financial Performance - The company's operating revenue for Q1 2024 reached ¥90,876,390.38, representing a year-on-year increase of 20.03%[3] - Net profit attributable to shareholders was ¥20,663,459.02, a significant increase of 209.02% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥20,186,561.37, reflecting a growth of 224.24% year-on-year[3] - Basic earnings per share rose to ¥0.0541, an increase of 205.65% compared to the previous year[3] - Operating profit for Q1 2024 was ¥21,980,744.79, compared to ¥7,425,391.87 in Q1 2023, reflecting a significant increase[13] - Net profit for Q1 2024 was ¥20,663,459.02, up 208.36% from ¥6,686,853.20 in Q1 2023[14] - Earnings per share for Q1 2024 were ¥0.0541, compared to ¥0.0177 in Q1 2023, indicating improved profitability per share[14] Cash Flow and Investments - The net cash flow from operating activities increased by 233.10% to ¥15,106,346.65, driven by increased cash inflows from pharmaceutical R&D projects[5] - Cash flow from operating activities for Q1 2024 was ¥15,106,346.65, a turnaround from a negative cash flow of -¥11,349,578.00 in Q1 2023[16] - The company reported a significant increase in cash inflow from operating activities, totaling ¥105,461,843.88 in Q1 2024, compared to ¥66,346,463.62 in Q1 2023[16] - Investment activities resulted in a net cash outflow of -¥137,235,223.73 in Q1 2024, compared to -¥54,170,453.07 in Q1 2023, indicating increased investment activity[16] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,089,670,586.06, up 2.60% from the end of the previous year[3] - The company's total assets as of March 31, 2024, amount to CNY 1,089,670,586.06, an increase from CNY 1,062,010,154.10 at the end of 2023[12] - The total current assets are CNY 584,415,472.04, compared to CNY 564,767,786.61 at the end of 2023, reflecting an increase of approximately 3.1%[9] - The total liabilities amount to CNY 360,628,366.37, up from CNY 355,394,780.03 at the end of 2023[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 31,063[6] - The top 10 shareholders hold a total of 20.83% of shares, with Xinjiang Hualing Industrial Trade Group Co., Ltd. being the largest shareholder at 79,525,087 shares[6] - The company's equity attributable to shareholders increased by 3.17% to ¥729,042,219.69[3] - The company's equity attributable to shareholders is CNY 729,042,219.69, an increase from CNY 706,615,374.07 at the end of 2023[12] Inventory and Receivables - The increase in accounts receivable by 57.87% was primarily due to the completion of pharmaceutical R&D projects reaching receivable milestones[4] - The inventory as of March 31, 2024, is CNY 132,026,260.69, compared to CNY 124,831,576.68 at the end of 2023, showing an increase of approximately 5.5%[9] - The company reported a 226.00% increase in credit impairment losses, mainly due to increased provisions for receivables based on credit risk characteristics[5] Research and Development - Research and development expenses for Q1 2024 were ¥6,001,053.66, slightly down from ¥6,139,950.63 in Q1 2023[13]